Clinical Context
Dexamethasone is a cornerstone of modern anesthetic practice, widely used for prevention of postoperative nausea and vomiting (PONV). Standard PONV prophylaxis protocols typically include dexamethasone 4-8 mg as a single intraoperative dose, which reduces PONV by approximately 25%. The drug also provides anti-inflammatory benefits that may reduce surgical swelling and improve early recovery.
However, glucocorticoids predictably elevate blood glucose through multiple mechanisms: increased hepatic gluconeogenesis, peripheral insulin resistance, and direct pancreatic effects. For patients with diabetes, this hyperglycemic effect raises concerns about perioperative glucose management, wound healing, and infection risk. The question of whether a single prophylactic dexamethasone dose significantly affects glucose in well-controlled diabetic patients has practical implications for millions of surgical patients annually.
Balancing the established anti-emetic benefits against potential glucose excursions requires understanding the magnitude and duration of hyperglycemic effects in both diabetic and non-diabetic patients.
PICO Summary
Population: Adult surgical patients including both non-diabetic individuals and well-controlled diabetic patients undergoing general anesthesia.
Intervention: Single intraoperative dose of dexamethasone administered at induction of anesthesia.
Comparison: Saline placebo administered at the same time point during anesthesia.
Outcome: Dexamethasone caused statistically significant increases in blood glucose in both diabetic and non-diabetic patients (P < 0.05). However, no patient exhibited glucose levels exceeding 180 mg/dL within 8 hours post-administration—a clinically meaningful threshold. Dexamethasone effectively reduced PONV within the first 24 hours after surgery. No serious adverse events were attributable to the glucose effect.
Clinical Pearls
1. Statistical vs Clinical Significance: While dexamethasone significantly increased glucose levels statistically, no patient exceeded 180 mg/dL—the threshold above which perioperative hyperglycemia is associated with increased infection and poor wound healing. This suggests the glucose effect, while real, remains within clinically acceptable bounds for well-controlled diabetic patients.
2. Well-Controlled Diabetes Key: The study included well-controlled diabetic patients. Results may not extend to patients with poorly controlled diabetes (HbA1c >9%), where baseline hyperglycemia plus dexamethasone effect could exceed safe thresholds. Patient selection is important.
3. Anti-Emetic Benefit Preserved: The study confirmed dexamethasone’s PONV reduction efficacy, supporting its continued use. PONV has significant patient experience and cost implications (extended PACU stays, unplanned admissions); the benefit should not be sacrificed for modest glucose concerns in appropriate patients.
4. Time Course Matters: Glucose levels were monitored within 8 hours—the period of peak dexamethasone effect. The transient nature of this hyperglycemia differs from sustained elevations that cause perioperative complications.
Practical Application
Single-dose perioperative dexamethasone for PONV prophylaxis appears safe for well-controlled diabetic patients, with glucose elevations remaining below clinically concerning thresholds. Do not withhold dexamethasone from diabetic patients solely due to glucose concerns if diabetes is well-controlled and the patient is at risk for PONV.
Consider closer glucose monitoring in diabetic patients receiving dexamethasone, particularly in the first 6-8 hours postoperatively. For patients whose preoperative glucose is already elevated (>180 mg/dL), consider alternative PONV prophylaxis (ondansetron, scopolamine) or plan for insulin coverage.
For poorly controlled diabetic patients, weigh the PONV prevention benefit against the additive hyperglycemic effect. In high-risk procedures where glucose control is critical (cardiac surgery, major vascular surgery), alternative anti-emetics may be preferred.
Broader Evidence Context
Multiple studies have examined dexamethasone’s glycemic effects, with varying conclusions depending on dose, population, and outcome definitions. Meta-analyses generally confirm modest glucose elevations that are clinically manageable in most patients. The PADDI trial (Perioperative Administration of Dexamethasone and Infection) examined surgical site infection risk with perioperative dexamethasone in diabetic patients, providing additional context on safety.
Guidelines from enhanced recovery after surgery (ERAS) protocols continue to recommend dexamethasone for appropriate patients, acknowledging the glucose effect while noting its transient nature and clinical manageability.
Study Limitations
Specific dexamethasone dose wasn’t detailed in the summary—effects may vary with dose. Only well-controlled diabetic patients were included; results may not apply to poorly controlled diabetes. Sample size and specific glucose values weren’t provided. Duration of glucose elevation beyond 8 hours wasn’t assessed.
Bottom Line
Single-dose intraoperative dexamethasone for PONV prophylaxis causes statistically significant but clinically modest glucose elevations in both diabetic and non-diabetic patients, with no values exceeding 180 mg/dL. For well-controlled diabetic patients, the PONV prevention benefits support continued dexamethasone use with appropriate glucose monitoring.
Source: Rose N, et al. “The Effect of Single Intraoperative Dose of Dexamethasone on the Blood Glucose Concentration in Diabetic and Non-Diabetic Patients: A Double Blinded Randomized Control Study.” Read article
